Loading...

Sun Pharma Advanced Research

NSEI:SPARC
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SPARC
NSEI
₹47B
Market Cap
  1. Home
  2. IN
  3. Pharmaceuticals & Biotech
Company description

Sun Pharma Advanced Research Company Limited engages in the research and development of pharmaceutical products in India and internationally. The last earnings update was 77 days ago. More info.


Add to Portfolio Compare Print
SPARC Share Price and Events
7 Day Returns
-4.3%
NSEI:SPARC
-0%
IN Pharmaceuticals
0.8%
IN Market
1 Year Returns
-58.5%
NSEI:SPARC
1%
IN Pharmaceuticals
-0.7%
IN Market
SPARC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Sun Pharma Advanced Research (SPARC) -4.3% -8.3% -0.7% -58.5% -39.6% 14%
IN Pharmaceuticals -0% 1.5% 3.7% 1% -11.1% 36.2%
IN Market 0.8% 2.8% 5.9% -0.7% 41.2% 72.5%
1 Year Return vs Industry and Market
  • SPARC underperformed the Pharmaceuticals industry which returned 1% over the past year.
  • SPARC underperformed the Market in India which returned -0.7% over the past year.
Price Volatility
SPARC
Industry
5yr Volatility vs Market

Value

 Is Sun Pharma Advanced Research undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Sun Pharma Advanced Research. This is due to cash flow or dividend data being unavailable. The share price is ₹175.55.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Sun Pharma Advanced Research's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Sun Pharma Advanced Research's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NSEI:SPARC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in INR ₹-5.28
NSEI:SPARC Share Price ** NSEI (2019-04-22) in INR ₹175.55
India Pharmaceuticals Industry PE Ratio Median Figure of 112 Publicly-Listed Pharmaceuticals Companies 20.2x
India Market PE Ratio Median Figure of 2,738 Publicly-Listed Companies 16.33x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Sun Pharma Advanced Research.

NSEI:SPARC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NSEI:SPARC Share Price ÷ EPS (both in INR)

= 175.55 ÷ -5.28

-33.26x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sun Pharma Advanced Research is loss making, we can't compare its value to the IN Pharmaceuticals industry average.
  • Sun Pharma Advanced Research is loss making, we can't compare the value of its earnings to the India market.
Price based on expected Growth
Does Sun Pharma Advanced Research's expected growth come at a high price?
Raw Data
NSEI:SPARC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -33.26x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
India Pharmaceuticals Industry PEG Ratio Median Figure of 32 Publicly-Listed Pharmaceuticals Companies 1.39x
India Market PEG Ratio Median Figure of 585 Publicly-Listed Companies 1.32x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Sun Pharma Advanced Research, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Sun Pharma Advanced Research's assets?
Raw Data
NSEI:SPARC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in INR ₹8.72
NSEI:SPARC Share Price * NSEI (2019-04-22) in INR ₹175.55
India Pharmaceuticals Industry PB Ratio Median Figure of 133 Publicly-Listed Pharmaceuticals Companies 1.88x
India Market PB Ratio Median Figure of 3,628 Publicly-Listed Companies 1.11x
NSEI:SPARC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NSEI:SPARC Share Price ÷ Book Value per Share (both in INR)

= 175.55 ÷ 8.72

20.14x

* Primary Listing of Sun Pharma Advanced Research.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sun Pharma Advanced Research is overvalued based on assets compared to the IN Pharmaceuticals industry average.
X
Value checks
We assess Sun Pharma Advanced Research's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Sun Pharma Advanced Research has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Sun Pharma Advanced Research expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sun Pharma Advanced Research has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
20.6%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Sun Pharma Advanced Research expected to grow at an attractive rate?
  • Unable to compare Sun Pharma Advanced Research's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Sun Pharma Advanced Research's earnings growth to the India market average as no estimate data is available.
  • Unable to compare Sun Pharma Advanced Research's revenue growth to the India market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NSEI:SPARC Future Growth Rates Data Sources
Data Point Source Value (per year)
India Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 20.6%
India Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 13.4%
India Market Earnings Growth Rate Market Cap Weighted Average 18.5%
India Market Revenue Growth Rate Market Cap Weighted Average 11.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NSEI:SPARC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in INR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NSEI:SPARC Future Estimates Data
Date (Data in INR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
NSEI:SPARC Past Financials Data
Date (Data in INR Millions) Revenue Cash Flow Net Income *
2018-12-31 1,181 -1,336
2018-09-30 1,177 -1,226
2018-06-30 717 -1,826
2018-03-31 783 -1,828 -1,970
2017-12-31 998 -2,326
2017-09-30 1,034 -2,405
2017-06-30 1,829 -1,630
2017-03-31 1,810 -1,280 -1,190
2016-12-31 1,827 -976
2016-09-30 1,932 -723
2016-06-30 1,415 -1,048
2016-03-31 1,613 -442 -700

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Sun Pharma Advanced Research is high growth as no earnings estimate data is available.
  • Unable to determine if Sun Pharma Advanced Research is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NSEI:SPARC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Sun Pharma Advanced Research Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NSEI:SPARC Future Estimates Data
Date (Data in INR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
NSEI:SPARC Past Financials Data
Date (Data in INR Millions) EPS *
2018-12-31 -5.28
2018-09-30 -4.86
2018-06-30 -7.33
2018-03-31 -7.94
2017-12-31 -9.44
2017-09-30 -9.69
2017-06-30 -6.62
2017-03-31 -4.84
2016-12-31 -3.99
2016-09-30 -2.99
2016-06-30 -4.37
2016-03-31 -2.96

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Sun Pharma Advanced Research will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Sun Pharma Advanced Research's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Sun Pharma Advanced Research's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Sun Pharma Advanced Research's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Sun Pharma Advanced Research's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the India market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the India market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Sun Pharma Advanced Research has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Sun Pharma Advanced Research performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Sun Pharma Advanced Research's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Sun Pharma Advanced Research does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Sun Pharma Advanced Research's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Sun Pharma Advanced Research's 1-year growth to the IN Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Sun Pharma Advanced Research's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Sun Pharma Advanced Research Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NSEI:SPARC Past Revenue, Cash Flow and Net Income Data
Date (Data in INR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 1,181.29 -1,335.98 1,034.76 1,050.02
2018-09-30 1,176.69 -1,226.48 968.76 959.72
2018-06-30 716.80 -1,826.40 1,015.20 1,064.00
2018-03-31 782.59 -1,969.98 1,015.16 1,173.62
2017-12-31 997.75 -2,325.97 962.14 1,622.56
2017-09-30 1,034.05 -2,405.47 933.14 1,704.06
2017-06-30 1,829.35 -1,629.67 890.94 1,702.96
2017-03-31 1,810.25 -1,190.38 844.24 1,366.34
2016-12-31 1,827.45 -975.82 807.06 1,315.25
2016-09-30 1,932.45 -722.72 722.36 1,332.65
2016-06-30 1,414.75 -1,047.52 430.76 979.95
2016-03-31 1,612.82 -699.92 567.26 1,195.45
2015-12-31 1,628.08 -698.10 595.29 1,241.23
2015-09-30 1,605.38 -477.00 576.09 1,055.73
2015-06-30 1,633.28 -314.30 552.49 1,049.33
2015-03-31 1,557.38 -395.20 459.14 1,110.47
2014-12-31 1,556.10 -326.26 464.76 1,004.63
2014-09-30 1,872.80 172.54 457.46 818.13
2014-06-30 1,672.10 110.74 453.06 718.83
2014-03-31 1,670.30 303.24 443.52 527.37
2013-12-31 1,962.89 768.65 458.00 440.92
2013-09-30 1,375.59 218.05 439.00 451.92
2013-06-30 1,165.69 53.35 417.80 411.42
2013-03-31 872.79 -224.95 403.90 410.92
2012-12-31 196.67 -881.22 375.48 427.95
2012-09-30 199.57 -819.32 365.88 402.95
2012-06-30 252.77 -792.92 355.88 451.45

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Sun Pharma Advanced Research has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Sun Pharma Advanced Research has efficiently used its assets last year compared to the IN Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Sun Pharma Advanced Research improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Sun Pharma Advanced Research's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Sun Pharma Advanced Research has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Sun Pharma Advanced Research's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Sun Pharma Advanced Research's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Sun Pharma Advanced Research is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Sun Pharma Advanced Research's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Sun Pharma Advanced Research's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 196.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Sun Pharma Advanced Research Company Filings, last reported 3 months ago.

NSEI:SPARC Past Debt and Equity Data
Date (Data in INR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 2,230.80 10.90 1,433.60
2018-09-30 2,230.80 10.90 1,433.60
2018-06-30 1,847.20 17.40 1,089.00
2018-03-31 1,847.24 22.85 1,077.69
2017-12-31 1,414.90 16.40 709.30
2017-09-30 1,414.90 16.40 709.30
2017-06-30 1,596.48 31.37 798.60
2017-03-31 1,581.56 31.37 732.32
2016-12-31 2,582.50 22.30 1,870.40
2016-09-30 2,582.50 22.30 1,870.40
2016-06-30 318.02 557.48 127.49
2016-03-31 318.02 557.48 127.49
2015-12-31 805.00 191.70 67.70
2015-09-30 805.00 191.70 67.70
2015-06-30 997.99 42.12 173.44
2015-03-31 997.99 42.12 173.44
2014-12-31 1,281.10 32.80 75.90
2014-09-30 1,281.10 32.80 75.90
2014-06-30 1,392.99 51.86 130.55
2014-03-31 1,392.99 51.86 130.55
2013-12-31 1,107.20 575.60 459.70
2013-09-30 1,107.20 575.60 459.70
2013-06-30 1,084.31 810.56 1,036.30
2013-03-31 1,084.31 810.56 1,036.30
2012-12-31 -756.20 982.60 209.00
2012-09-30 -756.20 982.60 209.00
2012-06-30 -666.09 683.22 65.05
  • Sun Pharma Advanced Research's level of debt (0.5%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (51.3% vs 0.5% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Sun Pharma Advanced Research has less than a year of cash runway based on current free cash flow.
  • Sun Pharma Advanced Research has less than a year of cash runway if free cash flow continues to grow at historical rates of 58.4% each year.
X
Financial health checks
We assess Sun Pharma Advanced Research's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Sun Pharma Advanced Research has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Sun Pharma Advanced Research's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Sun Pharma Advanced Research dividends.
If you bought ₹2,000 of Sun Pharma Advanced Research shares you are expected to receive ₹0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Sun Pharma Advanced Research's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Sun Pharma Advanced Research's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NSEI:SPARC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
India Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 69 Stocks 0.7%
India Market Average Dividend Yield Market Cap Weighted Average of 1400 Stocks 1.4%
India Minimum Threshold Dividend Yield 10th Percentile 0.3%
India Bottom 25% Dividend Yield 25th Percentile 0.5%
India Top 25% Dividend Yield 75th Percentile 1.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NSEI:SPARC Future Dividends Estimate Data
Date (Data in ₹) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Sun Pharma Advanced Research has not reported any payouts.
  • Unable to verify if Sun Pharma Advanced Research's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Sun Pharma Advanced Research's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Sun Pharma Advanced Research has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Sun Pharma Advanced Research's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Sun Pharma Advanced Research afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Sun Pharma Advanced Research has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Sun Pharma Advanced Research's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Anil Raghavan
TENURE AS CEO 5 years
CEO Bio

Mr. Anil Raghavan has been the Chief Executive Officer of Sun Pharma Advanced Research Company Limited since April 24, 2014. Mr. Raghavan is a senior pharmaceutical services executive with significant global exposure spanning business strategy and operations. He served as the Managing Director of the India and Sri Lanka business of Quintiles and a member of the Asia Management Board. Under his watch, Quintiles India maintained strong double-digit revenue and operating surplus growth in a turbulent external business environment. He provided key inputs to help the global leadership team rethink their corporate strategy to sustain the enterprise leadership and executed several strategic partnerships. Prior to joining Quintiles, he spent a decade consulting with leading firms such as Arthur Andersen, KPMG and Cambridge Technology Partners. He helped the leadership teams of several companies in developing and evaluating strategies and improving business performance. He contributed significantly in setting up KPMG's media consulting group in India and contributed to growing Arthur Andersen's consulting business in the country. An active speaker at events, he has participated in several industry sector studies, working with business lobbies and industry associations to highlight sectoral opportunities and challenges. He serves as a Member of Advisory Board of Medwell Ventures Private Limited. Mr. Raghavan is a B.Tech. in Industrial Engineering from University of Kerala (College of Engineering, Trivandrum). He has a deep interest in the evolving technologies of the pharmaceutical R&D and health care delivery segments.

CEO Compensation
  • Insufficient data for Anil to compare compensation growth.
  • Insufficient data for Anil to establish whether their remuneration is reasonable compared to companies of similar size in India.
Management Team Tenure

Average tenure and age of the Sun Pharma Advanced Research management team in years:

4.5
Average Tenure
60.5
Average Age
  • The tenure for the Sun Pharma Advanced Research management team is about average.
Management Team

Dilip Shanghvi

TITLE
Chairman & MD
AGE
63
TENURE
7.1 yrs

Chetan Rajpara

TITLE
Chief Financial Officer
COMPENSATION
₹10M
TENURE
2.2 yrs

Debashis Day

TITLE
Compliance Officer & Company Secretary
COMPENSATION
₹3M
TENURE
3.9 yrs

Anil Raghavan

TITLE
Chief Executive Officer
TENURE
5 yrs

Subhas Bhowmick

TITLE
Senior Vice President
AGE
62

Trinadha Chitturi

TITLE
Senior Vice President of R&D
AGE
59

Nitin Dharmadhikari

TITLE
Executive Vice President of R&D (Formulation Development)
AGE
56

Siu-Long Yao

TITLE
Senior Vice President of Clinical Development & Operations

Nitin Damle

TITLE
Senior Vice President of Discovery Biology & Preclinical R&D

Kristine Nograles

TITLE
Vice President and Head of Dermatology & Rheumatology
Board of Directors Tenure

Average tenure and age of the Sun Pharma Advanced Research board of directors in years:

7.1
Average Tenure
62.5
Average Age
  • The tenure for the Sun Pharma Advanced Research board of directors is about average.
Board of Directors

Dilip Shanghvi

TITLE
Chairman & MD
AGE
63
TENURE
7.1 yrs

Sudhir Valia

TITLE
Non-Executive Director
COMPENSATION
₹360K
AGE
62
TENURE
13.1 yrs

Thennati Rajamannar

TITLE
Non-Executive Director
COMPENSATION
₹300K
AGE
56
TENURE
11.8 yrs

Bhavna Doshi

TITLE
Independent Director
COMPENSATION
₹630K
AGE
65

Ferzaan Engineer

TITLE
Additional Independent Director
COMPENSATION
₹420K
TENURE
1.9 yrs

Mark Simon

TITLE
Additional Independent Director
COMPENSATION
₹390K
TENURE
1.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (₹) Value (₹)
27. Mar 19 Sell Pratham Investments Company 15. Mar 19 18. Mar 19 -125,000 ₹199.43 ₹-24,928,704
21. Sep 18 Sell Jayant Sanghvi Individual 14. Sep 18 14. Sep 18 -10,000 ₹402.70 ₹-4,026,996
12. Sep 18 Sell Jayant Sanghvi Individual 03. Sep 18 06. Sep 18 -20,000 ₹402.35 ₹-8,046,999
04. Sep 18 Sell Jayant Sanghvi Individual 20. Aug 18 31. Aug 18 -247,490 ₹398.19 ₹-98,548,235
09. Aug 18 Sell Jayant Sanghvi Individual 03. Aug 18 08. Aug 18 -28,503 ₹362.81 ₹-10,341,127
X
Management checks
We assess Sun Pharma Advanced Research's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Sun Pharma Advanced Research has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Have Insiders Been Selling Sun Pharma Advanced Research Company Limited (NSE:SPARC) Shares?

So before you buy or sell Sun Pharma Advanced Research Company Limited (NSE:SPARC), you may well want to know whether insiders have been buying or selling. … But logic dictates you should pay some attention to whether insiders are buying or selling shares. … Sun Pharma Advanced Research Insider Transactions Over The Last Year.

Simply Wall St -

Those Who Purchased Sun Pharma Advanced Research Shares A Year Ago Have A 57% Loss To Show For It

Because Sun Pharma Advanced Research is loss-making, we think the market is probably more focussed on revenue and revenue growth, at least for now. … Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth. … In the last year Sun Pharma Advanced Research saw its revenue grow by 18%.

Simply Wall St -

Could The Sun Pharma Advanced Research Company Limited (NSE:SPARC) Ownership Structure Tell Us Something Useful?

If you want to know who really controls Sun Pharma Advanced Research Company Limited (NSE:SPARC), then you'll have to look at the makeup of its share registry. … With a market capitalization of ₹45b, Sun Pharma Advanced Research is a small cap stock, so it might not be well known by many institutional investors. … Check out our latest analysis for Sun Pharma Advanced Research

Simply Wall St -

Have Insiders Been Selling Sun Pharma Advanced Research Company Limited (NSE:SPARC) Shares?

So before you buy or sell Sun Pharma Advanced Research Company Limited (NSE:SPARC), you may well want to know whether insiders have been buying or selling. … View our latest analysis for Sun Pharma Advanced Research. … Sun Pharma Advanced Research Insider Transactions Over The Last Year.

Simply Wall St -

What Type Of Shareholder Owns Sun Pharma Advanced Research Company Limited's (NSE:SPARC)?

If you want to know who really controls Sun Pharma Advanced Research Company Limited (NSE:SPARC), then you'll have to look at the makeup of its share registry. … With a market capitalization of ₹78.5b, Sun Pharma Advanced Research is a decent size, so it is probably on the radar of institutional investors. … Check out our latest analysis for Sun Pharma Advanced Research

Simply Wall St -

How Does Sun Pharma Advanced Research Company Limited (NSE:SPARC) Affect Your Portfolio Returns?

For Sun Pharma Advanced Research Company Limited’s (NSE:SPARC) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. … Generally, an investor should consider two types of risk that impact the market value of SPARC. … The second type is market risk, one that you cannot diversify away, since it arises from macroeconomic factors which directly affects all the stocks in the market.

Simply Wall St -

Who Really Owns Sun Pharma Advanced Research Company Limited (NSE:SPARC)?

In this article, I will take a quick look at Sun Pharma Advanced Research Company Limited’s (NSEI:SPARC) recent ownership structure – an unconventional investing subject, but an important one. … View our latest analysis for Sun Pharma Advanced Research NSEI:SPARC Ownership_summary May 31st 18 Institutional Ownership SPARC's 18.69% institutional ownership seems enough to cause large share price movements in the case of significant share sell-off or acquisitions by institutions, particularly when there is a low level of public shares available on the market to trade. … Thus, investors should dig deeper into SPARC's business relations with these companies and how it can affect shareholder returns in the long-term.Next Steps: SPARC's considerably high level of institutional ownership calls for further analysis into its margin of safety.

Simply Wall St -

Was Sun Pharma Advanced Research Company Limited's (NSE:SPARC) Earnings Decline Part Of A Broader Industry Downturn?

After looking at Sun Pharma Advanced Research Company Limited's (NSEI:SPARC) latest earnings announcement (31 March 2018), I found it useful to revisit the company's performance in the past couple of years and assess this against the most recent figures. … See our latest analysis for Sun Pharma Advanced Research Commentary On SPARC's Past Performance To account for any quarterly or half-yearly updates, I use the ‘latest twelve-month’ data, which annualizes the most recent half-year data, or in some cases, the latest annual report is already the most recent financial year data. … NSEI:SPARC Income Statement May 23rd 18 We can further assess Sun Pharma Advanced Research's loss by looking at what the industry has been experiencing over the past few years.

Simply Wall St -

Should You Buy Sun Pharma Advanced Research Company Limited (NSE:SPARC) At INR414.3?

Sun Pharma Advanced Research Company Limited (NSEI:SPARC), a pharmaceuticals company based in India, saw significant share price volatility over the past couple of months on the NSEI, rising to the highs of ₹458 and falling to the lows of ₹377.35. … Another thing to keep in mind is that Sun Pharma Advanced Research’s share price is quite stable relative to the rest of the market, as indicated by its low beta. … If you are no longer interested in Sun Pharma Advanced Research, you can use our free platform to see my list of over 50 other stocks with a high growth potential.

Simply Wall St -

Sun Pharma Advanced Research Company Limited (NSE:SPARC): Time For A Financial Health Check

With this debt repayment, SPARC currently has ₹798.60M remaining in cash and short-term investments , ready to deploy into the business. … NSEI:SPARC Historical Debt May 1st 18 Is SPARC’s debt level acceptable? … Risk around debt is extremely low for SPARC, and the company also has the ability and headroom to increase debt if needed going forward.Next Steps: SPARC’s low debt is also met with low coverage.

Simply Wall St -

Company Info

Description

Sun Pharma Advanced Research Company Limited engages in the research and development of pharmaceutical products in India and internationally. It develops new chemical entities and products based on its proprietary novel drug delivery systems. The company’s core therapeutic areas of interest include oncology, inflammation, and neurodegenerative diseases, as well as developing abuse deterrent formulations. It offers Levetiracetam ER for epilepsy; and Xelpros eye drops for Glaucoma. The company is also developing salmeterol-fluticasone DPI for use in treatingasthma/COPD; Baclofen GRS for spasticity; Taclantis for the treatment of cancer; Brimonidine OD for glaucoma; SDN-021 for pain; K0706 and K0954 for chronic myeloid leukemia; and SUN-597 Topical for atopic dermatitis. In addition, it is developing K0706 for Parkinson’s disease; SCD-044 autoimmune disorders; Minocycline Topical for acne; and SDP-037 for ocular inflammation. Sun Pharma Advanced Research Company Limited has a research collaboration agreement with HitGen Ltd. to identify small molecule leads for targets of interest. The company was incorporated in 2006 and is based in Mumbai, India. Sun Pharma Advanced Research Company Limited is a subsidiary of Shanghvi Finance Pvt. Ltd.

Details
Name: Sun Pharma Advanced Research Company Limited
SPARC
Exchange: NSEI
Founded: 2006
₹47,164,585,680
262,025,476
Website: http://www.sparc.life
Address: Sun Pharma Advanced Research Company Limited
17-B, Mahal Industrial Estate,
Off Mahakali Caves Road,
Mumbai,
Maharashtra, 400093,
India
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NSEI SPARC Equity Shares National Stock Exchange of India IN INR 18. Jul 2007
BSE 532872 Equity Shares Mumbai Stock Exchange IN INR 18. Jul 2007
Number of employees
Current staff
Staff numbers
424
Sun Pharma Advanced Research employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/22 12:52
End of day share price update: 2019/04/22 00:00
Last estimates confirmation: 2018/05/08
Last earnings filing: 2019/02/04
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.